Headlands Technologies LLC Sells 8,124 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)

Headlands Technologies LLC reduced its holdings in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 49.4% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 8,318 shares of the company's stock after selling 8,124 shares during the period. Headlands Technologies LLC's holdings in Revolution Medicines were worth $364,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in RVMD. Geode Capital Management LLC boosted its holdings in Revolution Medicines by 12.7% during the fourth quarter. Geode Capital Management LLC now owns 4,086,199 shares of the company's stock valued at $180,171,000 after purchasing an additional 459,174 shares in the last quarter. B. Metzler seel. Sohn & Co. AG bought a new position in shares of Revolution Medicines during the 4th quarter worth approximately $752,000. California Public Employees Retirement System boosted its stake in Revolution Medicines by 17.3% in the 4th quarter. California Public Employees Retirement System now owns 268,289 shares of the company's stock valued at $11,735,000 after buying an additional 39,475 shares in the last quarter. Pictet Asset Management Holding SA grew its position in Revolution Medicines by 4,399.6% in the fourth quarter. Pictet Asset Management Holding SA now owns 712,596 shares of the company's stock valued at $31,169,000 after acquiring an additional 696,759 shares during the period. Finally, Norges Bank acquired a new position in Revolution Medicines during the fourth quarter worth $76,197,000. Institutional investors own 94.34% of the company's stock.

Remove Ads

Analysts Set New Price Targets

Several equities research analysts have recently commented on RVMD shares. UBS Group boosted their target price on shares of Revolution Medicines from $65.00 to $71.00 and gave the company a "buy" rating in a research note on Wednesday, January 8th. HC Wainwright upped their price objective on shares of Revolution Medicines from $72.00 to $73.00 and gave the stock a "buy" rating in a research note on Monday, March 3rd. Stifel Nicolaus dropped their price objective on shares of Revolution Medicines from $78.00 to $64.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. Needham & Company LLC reissued a "buy" rating and issued a $59.00 target price on shares of Revolution Medicines in a report on Tuesday. Finally, Wedbush reaffirmed an "outperform" rating and set a $67.00 price target on shares of Revolution Medicines in a report on Thursday, February 27th. Twelve research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Revolution Medicines presently has an average rating of "Buy" and an average price target of $65.23.

Revolution Medicines Stock Up 12.8 %

RVMD stock traded up $3.99 during midday trading on Wednesday, reaching $35.12. The stock had a trading volume of 4,708,769 shares, compared to its average volume of 1,435,184. The firm has a market cap of $6.53 billion, a price-to-earnings ratio of -9.78 and a beta of 1.37. Revolution Medicines, Inc. has a twelve month low of $29.17 and a twelve month high of $62.40. The business has a fifty day simple moving average of $38.71 and a two-hundred day simple moving average of $44.84.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last announced its quarterly earnings data on Wednesday, February 26th. The company reported ($1.12) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.01) by ($0.11). On average, equities analysts predict that Revolution Medicines, Inc. will post -3.49 earnings per share for the current fiscal year.

Insider Transactions at Revolution Medicines

In related news, COO Margaret A. Horn sold 3,058 shares of the company's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $39.04, for a total value of $119,384.32. Following the completion of the sale, the chief operating officer now owns 153,533 shares in the company, valued at $5,993,928.32. This represents a 1.95 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Jack Anders sold 1,864 shares of Revolution Medicines stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $39.04, for a total value of $72,770.56. Following the transaction, the chief financial officer now owns 115,006 shares in the company, valued at approximately $4,489,834.24. This represents a 1.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 16,660 shares of company stock worth $650,406 in the last three months. Insiders own 8.00% of the company's stock.

Revolution Medicines Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.